To study the long-term clinical outcome and treatment strategies of recurrent and chronic non-infectious anterior uveitis. .
Multicenter study of chronic and recurrent anterior uveitis patients from 2001 to 2020. Outcome measures included ocular complications, medical and surgical therapies and visual acuity measured at the beginning of follow-up, and at 1,2 and 5-years.
Included were 76 patients, with mean follow-up of 6.8 years. Idiopathic anterior uveitis was the most common etiology (57%). Immunomodulation was used in almost half of the cohort. Early initiation of IMAs was associated with a lower risk of developing glaucoma (P=0.019). Mean BCVA improved after 5 years in both groups. Early use of immunomodulation was correlated with a better visual outcome at 2 years (P=0.024).
Chronic and recurrent anterior uveitis are associated with increased risk for ocular complications, ocular surgeries and vision impairment. Early initiation of immunomodulation may be considered to improve outcome.